Table 2.
The relationship between the proportion of CD8/PD-1 TILs and clinical characteristics.
| Proportion of CD8+ TILs (%) | p | Proportion of CD8+/PD-1+ TILs (%) | p | Proportion of CD8+/PD1−TILs (%) | p | |
|---|---|---|---|---|---|---|
| Age, median (IQR)∗ | 0.135 | 0.430 | 0.139 | |||
| ≤55 | 30 (10) | 3 (5) | 20 (13) | |||
| >55 | 20 (20) | 2 (6) | 18 (15) | |||
| Histological grade, median (IQR)∗∗ | 0.452 | 0.322 | 0.749 | |||
| I | 30 (32) | 3 (10) | 26 (22) | |||
| II | 20 (20) | 2 (6) | 18 (14) | |||
| III | 30 (20) | 4 (6) | 24 (17) | |||
| Vascular invasion, median (IQR)∗ | 0.122 | 0.156 | 0.237 | |||
| No | 20 (20) | 3 (5) | 20 (17) | |||
| Yes | 20 (15) | 2 (4) | 18 (13) | |||
| Nerve invasion, median (IQR)∗ | 0.706 | 0.982 | 0.706 | |||
| No | 20 (20) | 3 (5) | 18 (17) | |||
| Yes | 20 (10) | 3 (5) | 19 (11) | |||
| Axillary lymph node metastasis, median (IQR)∗ | 0.032 | 0.335 | 0.018 | |||
| No | 30 (23) | 4 (8) | 24 (16) | |||
| Yes | 20 (20) | 2 (5) | 16 (13) |
∗Wilcoxon test. ∗∗Spearman correlation test.